POSCO (ADR) (PKX): This Company Looks Good for Value Investors, But Are There Drawbacks?

Page 1 of 2

Investors who wish to shift gears and look at an opportunity that has little or nothing to offer in the way of arbitrage may be interested in South Korean steel-making giant POSCO (ADR) (NYSE:PKX). Despite being one of the largest steel concerns in the world, POSCO routinely gets sidelined in favor of competitors like ArcelorMittal (ADR) (NYSE:MT) or even United States Steel Corporation (NYSE:X).

Although there may be some merit to the argument against POSCO (ADR) (NYSE:PKX)’s viability as a long-term investment, it is also true that the firm’s shares have been punished for no apparent reason. Its low book value suggests that it has room to run in a shaky environment for basic commodities like iron ore and coal. What’s more, its diversification into the liquid natural gas business provides it with some insulation from volatile iron and coal prices. Investors who wish to take a closer look at POSCO may start by comparing it to two of its closest competitors.

POSCO and its competitors

Although there are plenty of independent steel-makers in the world, POSCO (ADR) (NYSE:PKX) is regarded as especially similar to ArcelorMittal and United States Steel Corporation (NYSE:X). Whereas ArcelorMittal (ADR) (NYSE:MT) is a massive and growing conglomerate with operations and clients in virtually every stable country in the world, U.S. Steel is a legacy company that has suffered through repeated downsizing and adjustments over the past several decades.

Oddly, this discrepancy does not necessarily show in these three firms’ market capitalization figures. POSCO’s $22.5 billion market cap exceeds ArcelorMittal’s $22 billion. Then again, both numbers dwarf U.S. Steel’s market cap of just over $2.5 billion. Meanwhile, POSCO (ADR) (NYSE:PKX) earned a decent 2012 profit of $2.2 billion on sales of over $57 billion. ArcelorMittal (ADR) (NYSE:MT) managed a narrow loss of around $4 billion on revenue of more than $81 billion. U.S. Steel was profitable by the slimmest of margins; its $22 million take came on revenue of nearly $19 billion.

As is par for the course in this capital-intensive industry, all three of these companies have significant, but not overly burdensome debt loads. Whereas POSCO has about $22.5 billion in debt to around $6 billion in cash, ArcelorMittal has obligations valued at $26 billion and a cash hoard of about $8 billion. With $4 billion in debt to $733 million in cash, United States Steel Corporation (NYSE:X)’s proportional burden is similar.

Valuation and other notes

Value investors who look closely at POSCO should be immediately struck by the company’s low price-to-book ratio. At 0.63, it is even lower than the seemingly troubled U.S. Steel’s 0.77 figure. Interestingly, ArcelorMittal’s reading of 0.45 seems to make the Luxembourg-based firm an even better deal than its Korean rival. Then again, POSCO (ADR) (NYSE:PKX)’s forward P/E of 7.5 is almost laughably low, and it compares favorably to respective readings of 9.2 and 11 for ArcelorMittal and U.S. Steel.

For whatever reason, few mainstream market participants seem to want to own this company. If any reason for this is to be found on the company’s balance sheet, it is likely to be contained within POSCO (ADR) (NYSE:PKX)’s cash flow report. Although it has a seemingly strong operating cash flow of $6.6 billion, its levered free cash flow is around minus $640 million. In comparison, U.S. Steel has positive levered free cash flow to the tune of $93 million. With free cash flow of nearly $4 billion, ArcelorMittal is definitely in the best shape in this department. This discrepancy may be part of the reason that bloggers and market-watchers seem to favor ArcelorMittal.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!